Insider filing report for Changes in Beneficial Ownership
- Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
- Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
- Peter Lynch
What is insider trading>>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No.________)*
SUNSHINE BIOPHARMA INC.
(Name of Issuer)
COMMON STOCK, par value $0.001 per share
(Title of Class of Securities)
867781403
(CUSIP Number)
Malek Chamoun
1730 rue Saint Patrick Apt, 601
Montreal, Quebec, Canada H3K 0B2
(Name, Address and
Telephone Number of Person
Authorized to Receive Notices and Communications)
October 20, 2022
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| o | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| o | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
| CUSIP No. 867781403 | 13G |
| Malek Chamoun | |||||
| 1. | NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Not Applicable | ||||
| 2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) | ||||
| (a) | ☐ | ||||
| (b) | ☒ | ||||
| 3. | SEC USE ONLY
| ||||
| 4. | CITIZENSHIP
OR PLACE OF ORGANIZATION Canada | ||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH
WITH |
5. | SOLE VOTING POWER | |||
| 6. | SHARED VOTING POWER
0 | ||||
| 7. | SOLE DISPOSITIVE POWER | ||||
| 8. | SHARED DISPOSITIVE POWER
0 | ||||
| 9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON | ||||
| 10. | CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☐ | ||||
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) | ||||
| 12. | TYPE OF REPORTING PERSON (see instructions) | ||||
| 2 |
| CUSIP No. 867781403 | 13G |
| Item 1. | |||
| (a) | Name
of Issuer Sunshine Biopharma Inc. | ||
| (b) | Address of Issuer’s Principal Executive Offices 6500 Trans-Canada Hwy 4th Floor Pointe-Claire, Quebec, Canada H9R 0A5 | ||
| Item 2. | |||
| (a) | Name
of Person Filing Malek Chamoun | ||
| (b) | Address
of Principal Office, or if none, Residence Montreal, Quebec, Canada H3K 2H2 | ||
| (c) | Citizenship | ||
| (d) | Title
of Class of Securities Common Stock | ||
| (e) | CUSIP
Number | ||
| Item 3. | If this statement is filed pursuant to § 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: | ||
| (a) | o | Broker or dealer registered under section 15 of the Act. | |
| (b) | o | Bank as defined in section 3(a)(6) of the Act. | |
| (c) | o | Insurance company as defined in section 3(a)(19) of the Act. | |
| (d) | o | Investment company registered under section 8 of the Investment Company Act of 1940. | |
| (e) | o | An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); | |
| (f) | o | An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); | |
| (g) | o | A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); | |
| (h) | o | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; | |
| (i) | o | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; | |
| (j) | o | Group, in accordance with § 240.13d-1(b)(1)(ii)(J). | |
| 3 |
| CUSIP No. 867781403 | 13G |
| Item 4. | Ownership. | |
| Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. | ||
| (a) | Amount beneficially owned: 3,700,000 | |
| (b) | Percent of class: 16.4% |
| (c) | Number of shares as to which the person has: 3,700,000 | ||
| (i) | Sole power to vote or direct the vote 3,700,000 | ||
| (ii) | Shared power to vote or to direct the vote 0 |
| (iii) | Sole power to dispose or to direct the disposition of 3,700,000. |
| (iv) | Shared power to dispose or to direct the disposition of 0. |
| Item 5. | Ownership of Five Percent or Less of a Class.
| |
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐. | ||
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person.
| |
| Not Applicable. | ||
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
| |
| Not Applicable. | ||
| Item 8. | Identification and Classification of Members of the Group.
| |
| Not Applicable. | ||
| Item 9. | Notice of Dissolution of Group.
| |
| Not Applicable. | ||
| Item 10. | Certifications.
| |
| (a) | The following certification shall be included if the statement is filed pursuant to §240.13d-1(b):
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. | |
| (b) | The following certification shall be included if the statement is filed pursuant to §240.13d-1(c): | |
| 4 |
| CUSIP No. 867781403 | 13G |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| November 2, 2022 | ||||
| Date | ||||
| /s/ Malek Chamoun | ||||
| Signature | ||||
| Malek Chamoun | ||||
| Name/Title |
| 5 |